Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Ashley Mashall

Physician Assistant New York, NY Physician Assistant

NPI 1043847981 CMS profile 10873672

820 2Nd Ave Rm 3A, New York, NY 10017

Open in the dashboard

General payments

$7,864

311 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Mashall of New York, NY is reported in the CMS Open Payments database as having received $7,864 across 311 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,726 92
2024 General $1,852 63
2023 General $1,690 86
2022 General $1,596 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Mashall
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Ashley Mashall were reported at $2,726. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Ashley Mashall Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $1,596 $155 $48–$522 $149
2023 $1,690 $167 $52–$557 $160
2024 $1,852 $178 $55–$600 $164
2025 $2,726 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Janssen Biotech, Inc. $945 48 payments
  2. Genzyme Corporation $765 21 payments
  3. LEO Pharma Inc. $691 14 payments
  4. Sun Pharmaceutical Industries Inc. $665 28 payments
  5. AbbVie, Inc. $647 35 payments
  6. UCB, Inc. $624 29 payments
  7. Incyte Corporation $565 29 payments
  8. Lilly USA, LLC $557 21 payments
  9. Novartis Pharmaceuticals Corporation $540 25 payments
  10. Regeneron Healthcare Solutions, Inc. $410 10 payments
  11. Other $1,458 51 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $7,619 308 payments
  2. Education $245 3 payments
Products named General payments · program years 2022–2025
  1. TREMFYA $945 48 payments
  2. DUPIXENT Immunology $765 21 payments
  3. OPZELURA $565 29 payments
  4. ADBRY $533 12 payments
  5. COSENTYX $516 24 payments
  6. Bimzelx $498 23 payments
  7. TALTZ $386 18 payments
  8. DUPIXENT Immunology And Inflammation $335 6 payments
  9. ILUMYA $286 10 payments
  10. RINVOQ $279 11 payments
  11. Other $2,562 115 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

96

Median for Physician Assistant: 241

Drug cost

$816

Median for Physician Assistant: $4,110

Branded share of claims

0%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ketoconazole Generic 21 $296
Triamcinolone Acetonide Generic 40 $219
Hydrocortisone Generic 15 $172
Mupirocin Generic 20 $128

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $407
$407 — —
Bimzelx
  • UCB, Inc. $331
$331 — —
ADBRY
  • LEO Pharma Inc. $241
$241 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $177
$177 — —
OLUMIANT
  • Lilly USA, LLC $170
$170 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

311 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record